Sequenom Inc.
3595 John Hopkins Court
San Diego,
CA 92121-1331
United States - Map
Phone: 858-202-9000
Fax: 858-202-9001
Web Site: http://www.sequenom.com
| Sequenom, Inc. provides products, services, diagnostic testing, applications, and genetic analysis products that translate genomic science into solutions for biomedical research, translational research, molecular medicine, and agricultural and livestock applications. It offers MassARRAY system, a high performance nucleic acid analysis platform that measures genetic target material and variations. The company offers its MassARRAY system for various DNA/RNA analysis applications, including single nucleotide polymorphism (SNP), genotyping detection of mutations, analysis of copy number variants, and other structural genome variations, as well as quantitative gene expression analysis, quantitative methylation marker analysis, comparative sequence analysis of haploid organisms, SNP discovery, and oligonucleotide quality control. Sequenom also provides the iPLEX multiplexing assay reagents and chips, which permits multiplexed SNP analysis using a similar amount of reagents and chip surface area. In addition, the company engages in the research, development, and the commercialization of various non-invasive molecular diagnostic tests for prenatal genetic disorders and diseases, oncology, and infectious diseases. It offers its products through direct sales and support personnel to clinical research laboratories, bio-agriculture, bio-technology and pharmaceutical companies, academic institutions, and government agencies worldwide. Sequenom has a collaboration agreement with the Immune Tolerance Institute to develop an advanced newborn screening test for severe combined immunodeficiency. The company was founded in 1994 and is headquartered in San Diego, California with additional offices in Queensland, Australia; Beijing, China; and Newton, Massachusetts. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. Harry F. Hixson Jr., Ph.D., 70
Chairman, Interim Chief Exec. Officer, Member of Compensation Committee and Member of Nominating & Corp. Governance Committee |
$
52.00K | N/A | Dr. Harry Stylli M.B.A., Ph.D., 47
Pres and Exec. Director |
$
622.00K |
$
0 | Mr. Paul W. Hawran , 56
Chief Financial Officer and Principal Accounting Officer |
$
388.00K |
$
0 | Mr. Clarke Neumann J.D., 45
VP, Assistant Sec. and Gen. Counsel |
$
301.00K |
$
9.00K | Dr. Elizabeth Dragon Ph.D., 60
Sr. VP of R&D |
$
351.00K |
$
0 |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
2.03% Nasdaq 0.00%
Profile
